08:37 AM EDT, 03/27/2024 (MT Newswires) -- NovoCure ( NVCR ) said Wednesday that its Tumor Treating Fields therapy for brain metastases from non-small cell lung cancer met its primary endpoint in a phase 3 trial.

The therapy and supportive care slowed the progression of cancer to the brain to 21.9 months, compared with 11.3 months with supportive care alone, the company said.

Novocure ( NVCR ) said it will submit the clinical trial data to regulatory authorities, publish the findings in a peer-reviewed scientific journal, and share them at an upcoming conference.

Shares of the company were up nearly 30% in Wednesday's premarket activity.

Price: 16.71, Change: +3.64, Percent Change: +27.82